TW202206061A - 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 - Google Patents
苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 Download PDFInfo
- Publication number
- TW202206061A TW202206061A TW110139097A TW110139097A TW202206061A TW 202206061 A TW202206061 A TW 202206061A TW 110139097 A TW110139097 A TW 110139097A TW 110139097 A TW110139097 A TW 110139097A TW 202206061 A TW202206061 A TW 202206061A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- depression
- day
- benzoic acid
- derivatives
- Prior art date
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 239000005711 Benzoic acid Substances 0.000 title claims abstract description 40
- 235000010233 benzoic acid Nutrition 0.000 title claims abstract description 40
- 150000003839 salts Chemical class 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 34
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 25
- 208000024714 major depressive disease Diseases 0.000 claims description 22
- 235000010234 sodium benzoate Nutrition 0.000 claims description 22
- 239000004299 sodium benzoate Substances 0.000 claims description 22
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000000638 stimulation Effects 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 238000002635 electroconvulsive therapy Methods 0.000 claims description 5
- 229960001785 mirtazapine Drugs 0.000 claims description 5
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 5
- 229960002073 sertraline Drugs 0.000 claims description 5
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 230000007383 nerve stimulation Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 210000001186 vagus nerve Anatomy 0.000 claims description 4
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 3
- 229940086681 4-aminobenzoate Drugs 0.000 claims description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 3
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 229940050390 benzoate Drugs 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 235000010237 calcium benzoate Nutrition 0.000 claims description 3
- 239000004301 calcium benzoate Substances 0.000 claims description 3
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960002866 duloxetine Drugs 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 229960000685 levomilnacipran Drugs 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- PJJZFXPJNUVBMR-UHFFFAOYSA-L magnesium benzoate Chemical compound [Mg+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 PJJZFXPJNUVBMR-UHFFFAOYSA-L 0.000 claims description 3
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 claims description 3
- 229960002248 meradimate Drugs 0.000 claims description 3
- 229960001158 nortriptyline Drugs 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 235000010235 potassium benzoate Nutrition 0.000 claims description 3
- 239000004300 potassium benzoate Substances 0.000 claims description 3
- 229940103091 potassium benzoate Drugs 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 229960004431 quetiapine Drugs 0.000 claims description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 3
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 claims description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 3
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 229960004688 venlafaxine Drugs 0.000 claims description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 2
- XFDUHJPVQKIXHO-UHFFFAOYSA-M 3-aminobenzoate Chemical compound NC1=CC=CC(C([O-])=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-M 0.000 claims description 2
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 2
- 244000141009 Hypericum perforatum Species 0.000 claims description 2
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 2
- 229960002629 agomelatine Drugs 0.000 claims description 2
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims description 2
- 229960000836 amitriptyline Drugs 0.000 claims description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002519 amoxapine Drugs 0.000 claims description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004372 aripiprazole Drugs 0.000 claims description 2
- 229960001058 bupropion Drugs 0.000 claims description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 2
- 229960001653 citalopram Drugs 0.000 claims description 2
- 229960004606 clomipramine Drugs 0.000 claims description 2
- 229960003914 desipramine Drugs 0.000 claims description 2
- 229960001623 desvenlafaxine Drugs 0.000 claims description 2
- 229960005426 doxepin Drugs 0.000 claims description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 2
- 229960004341 escitalopram Drugs 0.000 claims description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 2
- 229960002464 fluoxetine Drugs 0.000 claims description 2
- 229960002419 flupentixol Drugs 0.000 claims description 2
- 229960004038 fluvoxamine Drugs 0.000 claims description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 2
- 229960004801 imipramine Drugs 0.000 claims description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002672 isocarboxazid Drugs 0.000 claims description 2
- 229960004090 maprotiline Drugs 0.000 claims description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 2
- 229960004794 melitracen Drugs 0.000 claims description 2
- GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960004644 moclobemide Drugs 0.000 claims description 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001800 nefazodone Drugs 0.000 claims description 2
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- 229960002296 paroxetine Drugs 0.000 claims description 2
- 229960000964 phenelzine Drugs 0.000 claims description 2
- 238000001126 phototherapy Methods 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002601 protriptyline Drugs 0.000 claims description 2
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 2
- 238000001671 psychotherapy Methods 0.000 claims description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 2
- 229960003946 selegiline Drugs 0.000 claims description 2
- 229960004940 sulpiride Drugs 0.000 claims description 2
- 238000011491 transcranial magnetic stimulation Methods 0.000 claims description 2
- 229960003741 tranylcypromine Drugs 0.000 claims description 2
- 229960003991 trazodone Drugs 0.000 claims description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002431 trimipramine Drugs 0.000 claims description 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960003740 vilazodone Drugs 0.000 claims description 2
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002263 vortioxetine Drugs 0.000 claims description 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 229960005137 succinic acid Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 13
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- -1 3-aminobenzoic acid Ester Chemical class 0.000 description 5
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 5
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 206010011971 Decreased interest Diseases 0.000 description 2
- 206010012374 Depressed mood Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 101100257062 Leishmania major IPCS gene Proteins 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YOJXPNNNKZABFE-QRLADXQJSA-N (2r)-2-azanyl-3-oxidanyl-propanoic acid Chemical compound OC[C@@H](N)C(O)=O.OC[C@@H](N)C(O)=O YOJXPNNNKZABFE-QRLADXQJSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000015404 Amino Acid Receptors Human genes 0.000 description 1
- 108010025177 Amino Acid Receptors Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- JPRXYLQNJJVCMZ-UHFFFAOYSA-N Rizatriptan benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1.C1=C2C(CC[NH+](C)C)=CNC2=CC=C1CN1C=NC=N1 JPRXYLQNJJVCMZ-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- KEJICOXJTRHYAK-XFULWGLBSA-N alogliptin benzoate Chemical compound OC(=O)C1=CC=CC=C1.C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 KEJICOXJTRHYAK-XFULWGLBSA-N 0.000 description 1
- 229960000447 alogliptin benzoate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003282 amino acid receptor affecting agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 description 1
- 229960000870 betamethasone benzoate Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PWPDEXVGKDEKTE-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol;hydrate Chemical compound O.OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 PWPDEXVGKDEKTE-UHFFFAOYSA-N 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- GJBRTCPWCKRSTQ-UHFFFAOYSA-N decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.OC(=O)CCCCCCCCC(O)=O GJBRTCPWCKRSTQ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960004981 desvenlafaxine succinate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004789 rizatriptan benzoate Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
- A61N1/36096—Mood disorders, e.g. depression, anxiety or panic disorder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/002—Magnetotherapy in combination with another treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Radiology & Medical Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Developmental Disabilities (AREA)
- Child & Adolescent Psychology (AREA)
- Social Psychology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本揭露提供一種用於預防或治療有需要的個體之憂鬱症之方法,所述方法包括對個體施用有效量的苯甲酸或其鹽及衍生物。本揭露亦提供一種用於預防或治療有需要的個體之憂鬱症之組成物。
Description
本揭露係關於憂鬱症的預防或治療,尤其係指一種投予包含苯甲酸或其鹽及衍生物的組成物至有需要的個體以預防或治療憂鬱症之方法。本揭露亦有關於一種用於預防或治療有需要的個體之憂鬱症之組成物。
重度憂鬱症(major depressive disorder,MDD,簡稱重鬱症)是一種嚴重且常見的精神疾病。重鬱症是自殺的主要原因(Harwood,Hawton et al.2001;Waern,Runeson et al.2002)且和失能、疼痛(Ohayon and Schatzberg 2003)、認知障礙(Steffens,Skoog et al.2000;Mecocci,Cherubini et al.2004)及醫療資源和社會福利的不必要使用(VanValkenburg,Akiskal et al.1984;Saravay and Lavin,1994)有關,尤其是在老年人口中。由於其發病率和死亡率過高(Miu and Chan 2010),憂鬱症已經成為政府和大眾需要認真看待的一個重大公共衛生問題。
重鬱症是一種複雜且多因子的疾病,其病因不能由單
一基因或單一環境因素來解釋(Dagyte,Den Boer et al.2011)。目前大多數的抗憂鬱藥都是基於單胺(例如,血清素、去甲基腎上腺素及多巴胺)假說(Charney 1998)。然而,療效通常需要超過3到4週始有作用,且約有30%至60%的重鬱症患者無法復原(Riihimaki,Vuorilehto et al.2014;Keller,Lavori et al.1992),這意味著單胺假說無法完全解釋憂鬱症的病因。發表在《刺胳針(Lancet)》上的一篇論文比較了舍曲林(sertraline)、米氮平(mirtazapine)及安慰劑用於治療失智症患者之憂鬱症之療效。結果顯示,抗憂鬱藥群組(舍曲林及米氮平)和安慰劑群組在減少憂鬱指數上並沒有差別(Banerjee,Hellier et al.2011);此外,抗憂鬱藥群組與安慰劑群組相比明顯有更多的不良反應(42%對26%)。這項樣本量龐大且長時間持續跟進的研究的負面結果,表明了應重新考慮使用抗憂鬱藥作為治療阿茲海默症中的憂鬱之第一線療法。許多患者在使用抗憂鬱藥治療之後具有顯著的副作用,像是腸胃不適、心臟毒性、抗膽鹼作用、鎮靜或躁動、失眠及低血鈉症,這阻礙了治療的動機和服藥依順性。因此,非常需要為重鬱症患者開發經由單胺理論以外的機制並具有更佳功效及更安全不良反應態樣的新穎療法。
麩胺酸(glutamate)是哺乳動物腦中最豐富的胺基酸神經傳導物質,而N-甲基-D-天門冬胺酸(N-methyl-D-aspartate,NMDA)受體是離子型麩胺酸受體的一個子類型,在神經認知及神經毒性上扮演重要的角色。憂鬱症可能含
有複雜的神經受質,因其包含了NMDA的正調控及負調控功能。NMDA受體廣泛地分佈在皮質邊緣迴路(corticolimbic circuitries)中,像憂鬱症這種複雜行為障礙包含多個可具有相反調節方向的NMDA受體迴路並不令人訝異。
NMDA的機能低下(hypofunction)可能涉及憂鬱症的病理生理學。在患有嚴重憂鬱症個體死後的腦中,其NMDA受體1及2A次單元的表現量是減少的(Beneyto & Meador-Woodruff 2008),且在自殺死者中,NMDA受體的結合減少(Nowak,Ordway et al.1995)。增強NMDA的途徑代表了治療憂鬱症的新穎治療方法。
D-胺基酸氧化酶(D-amino acid oxidase,DAAO)是一種存在於哺乳動物的腦、腎臟及肝臟中的過氧化體的一種黃素酶,其係負責降解D-絲胺酸(D-serine)、D-丙胺酸(D-alanine)和其他D-胺基酸(D-amino acids)(Fukui & Miyake 1992;Vanoni,Cosma et al.1997)。增強NMDA功能的一種方法是透過抑制DAAO的活性。苯甲酸和苯甲酸鈉可以抑制DAAO的活性,從而提高D-絲胺酸和其他D-胺基酸的突觸濃度(Bartlett 1948;Van den Berghe-Snorek & Stankovich 1985)。苯甲酸天然地存在於許多植物和動物中,因此,它是許多食品的天然成分,包括奶製品(IPCS 1993)。苯甲酸和苯甲酸鈉在美國(Joint FAO/WHO Expert Committee on Food Additives.1965,1973)、台灣(衛生署)及世界衛生組織(IPCS 1993)也是合法的食品添加物,而
且被廣泛地使用在製造果凍、奶油、醬油和加工肉類等。
為了測試苯甲酸或其鹽及衍生物對憂鬱症是否係有益的,發明人進行本揭露之試驗,以檢驗苯甲酸或其鹽及衍生物對於憂鬱症患者之功效及安全性。
根據前述內容,本揭露提供一種預防或治療憂鬱症的方法,其包括向有需要的個體施用有效量的苯甲酸或其鹽及衍生物及醫藥上可接受之賦形劑。
在本揭露之實施例中,個體被診斷患有失智症。在一實施例中,該失智症包括阿茲海默症、血管性癡呆、路易氏體型失智症、額顯葉型失智症、綜合型失智症、由疾病或物質使用引起的失智症、常壓性水腦症、帕金森失智症、梅毒或庫賈氏病,但不以此為限。
在本揭露之實施例中,苯甲酸鹽及其衍生物係選自苯甲酸鈉、苯甲酸鉀、苯甲酸鈣、苯甲酸鎂、2-胺基苯甲酸酯、3-胺基苯甲酸酯、4-胺基苯甲酸酯、4-羥基苯甲酸乙酯、4-羥基苯甲酸乙酯鈉、4-羥基苯甲酸丙酯、4-羥基苯甲酸丙酯鈉、4-羥基苯甲酸甲酯或4-羥基苯甲酸甲酯鈉,但不以此為限。
在本揭露之另一實施例中,苯甲酸鹽及其衍生物係為苯甲酸鈉。
在本揭露之實施例中,憂鬱症包括重度憂鬱症(MDD)、老年憂鬱症(geriatric depression)、老年人憂鬱症(elderly depression)或晚年憂鬱症(late-life depression),但不以
此為限。
在本揭露之實施例中,苯甲酸或其鹽及衍生物對有需要的個體的施用量可為從100毫克(mg)/天至2500mg/天、從200mg/天至2000mg/天、從250mg/天至1500mg/天、從250mg/天至1000mg/天、從500mg/天至1000mg/天或從600mg/天至800mg/天。
在本揭露之實施例中,醫藥上可接受之賦形劑係選自由填料、黏合劑、防腐劑、崩散劑、潤滑劑、懸浮劑、潤濕劑、溶劑、界面活性劑、酸、調味劑、聚乙二醇(polyethylene glycol,PEG)、烷二醇(alkylene glycol)、癸二酸(sebacic acid)、二甲基亞碸(dimethyl sulfoxide)、醇及其任一組合所組成之群組中之一者。
在本揭露之實施例中,苯甲酸或其鹽及衍生物作為組成物中預防或治療憂鬱症之唯一活性成分,或者苯甲酸或其鹽及衍生物係與預防或治療憂鬱症之其他活性成分併用。在一實施例中,其他活性成分包括選自度洛西汀(duloxetine)、左旋米那普侖(levomilnacipran)、文拉法辛(venlafaxine)、琥珀酸去甲文拉法辛(desvenlafaxine)、西酞普蘭(citalopram)、艾司西酞普蘭(escitalopram)、氟西汀(fluoxetine)、氟伏沙明(fluvoxamine)、帕羅西汀(paroxetine)、舍曲林(sertraline)、阿米替林(amitriptyline)、安莫散平(amoxapine)、氯米帕明(clomipramine)、地昔帕明(desipramine)、多慮平(doxepin)、伊米帕明(imipramine)、去甲替林
(nortriptyline)、普羅替林(protriptyline)、曲米帕明(trimipramine)、馬普替林(maprotiline)、安非他酮(bupropion)、維拉佐酮(vilazodone)、奈法唑酮(nefazodone)、曲唑酮(trazodone)、沃替西汀(vortioxetine)、異卡波肼(isocarboxazid)、苯乙肼(phenelzine)、司來吉蘭(selegiline)、反苯環丙胺(tranylcypromine)、米氮平(mirtazapine)、奧氮平(olanzapine)、喹硫平(quetiapine)、阿立哌唑(aripiprazole)、舒必利(sulpiride)、氟哌噻噸(flupentixol)、美利曲辛(melitracen)、阿戈美拉汀(agomelatine)、嗎氯貝胺(moclobemide)、貫葉連翹(St.John's wort)、S-腺苷甲硫氨酸(S-adenosyl-L-methionine)及其任一組合所組成之群組中之一者,但不以此為限。
在本揭露之實施例中,苯甲酸或其鹽及衍生物的給藥包括預防或治療憂鬱症之其他療程。在一實施例中,該其他療程係選自由心理治療、電痙攣療法(electroconvulsive therapy,ECT)、腦刺激療法、光照治療及其任一組合所組成之群組中之一者。在一實施例中,該腦刺激療法係腦深層刺激、侵入性迷走神經刺激、透顱磁刺激、透顱直流電刺激、透顱交流電刺激、電痙攣療法、磁振癲癇發作治療、經顱微電流刺激療法或非侵入性迷走神經刺激。
以下實施例係用於例示本揭露之揭示內容。所屬技術領域中具有通常知識者基於此說明書之揭示內容,能明顯理解本揭露之其他優點。如文中所述,本揭露亦可以不同的實施例來實現或應用。為了實現本揭露,在不違背其精神及範圍下,可能修改及/或改變上述實施例,以用於不同的層面及應用上。
本文中所使用包括描述性術語或技術性術語的所有術語應被理解為具有對於所屬技術領域中具有通常知識者係顯而易知的意義。然而,根據所屬技術領域中具有通常知識者之意圖、前案或新出現的技術,該術語可具有不同的意義。有些術語也可由申請者任意挑選,在此狀況下,所選擇的術語將詳盡地描述於本揭露的詳細描述中。因此,本文中所使用之術語必須基於術語之意義及整篇說明書的描述而定義。
同樣的,本案中當「包括」或「包含」組成分或步驟時,除非另有特別的說明,可進一步包括其他的組成分或其他的步驟,而非排除該等其他的組成分或其他的步驟。
須進一步注意的是,除非特別地及明確地限定於單一個指示,如本說明書中所使用之單數形式「一」(a)、「一」(an)及「該」應包含複數指示。除非上下文另有明確說明,術語「或」可與術語「及/或」互換使用。
本揭露提供一種治療或預防個體的憂鬱症或重鬱症之方法,該個體係患有憂鬱症或重鬱症。在本揭露之某些實施例中,該個體被臨床診斷罹患憂鬱症或憂鬱症的相關情
緒障礙,例如重鬱症。如本文中所使用,術語「憂鬱症」係指一種常見的精神疾病,其特徵為普遍性情緒低落、失去對日常活動的興趣或樂趣、內疚感或自我價值低落感、失眠或食慾不振、精力不足和注意力不集中。憂鬱症可能導致各種情緒和身體的問題,並可能降低一個人在工作和在家的運作能力。最糟的狀況下,憂鬱症可能導致自殺。術語「憂鬱症」也包括憂鬱性的失調,例如情緒障礙、重度低落性情感疾患及重鬱症(一般稱為重度憂鬱症或臨床憂鬱症)。患有重鬱症的人會有至少兩個禮拜情緒低落,或者在幾乎所有活動中失去興趣或樂趣。
在本揭露之某些實施例中,所述方法包括對該個體投予包含有效量之苯甲酸或其鹽及衍生物。在本揭露之某些實施例中,苯甲酸或其鹽及衍生物的有效量可為從100mg/天至2500mg/天,例如從200mg/天至2000mg/天、從250mg/天至1500mg/天、從250mg/天至1500mg/天、從250mg/天至1000mg/天、從500mg/天至1000mg/天、從500mg/天至900mg/天、從600mg/天至800mg/天或約900mg/天、約775mg/天、約500mg/天、或約250mg/天。在本揭露之某些實施例中,苯甲酸或其鹽及衍生物的有效量為約250mg/天、約500mg/天、約750mg/天、約1000mg/天、約1250mg/天或約1500mg/天。在本揭露之某些實施例中,苯甲酸或其鹽及衍生物的下限劑量可為100mg/天、200mg/天、250mg/天、500mg/天、600mg/天、750mg/天、775mg/天、800mg/天、900mg/天、1000mg/天、1250
mg/天、1500mg/天或2000mg/天,且苯甲酸或其鹽及衍生物的上限劑量可為2500mg/天、2000mg/天、1500mg/天、1250mg/天、1000mg/天、900mg/天、800mg/天、775mg/天、750mg/天、600mg/天、500mg/天、250mg/天或200mg/天。
在本揭露之某些實施例中,對個體投予的苯甲酸或其鹽及衍生物係包含在醫藥組成物中。本揭露之醫藥組成物包括苯甲酸或其鹽及衍生物及其醫藥上可接受之賦形劑。在一實施例中,本揭露之組成物係調配成適於口服之形式,因此,該組成物可經由口服遞送對該個體投予。或者,該組成物可調配成乾粉、片劑、錠劑、膠囊、顆粒或丸劑之形式。醫藥上可接受之賦形劑包括填料、黏合劑、防腐劑、崩散劑、潤滑劑、懸浮劑、潤濕劑、溶劑、界面活性劑、酸、調味劑、聚乙二醇、烷二醇、癸二酸、二甲基亞碸、醇及其組合,但不以此為限。
在本揭露之一些實施例中,投予包含苯甲酸或其鹽及衍生物之組成物可以一天一次、一天兩次、一天三次或一天四次進行。在本揭露之一些實施例中,係每天投予包含苯甲酸或其鹽及衍生物之組成物超過至少四週。在本揭露之一些實施例中,係每天投予包含苯甲酸或其鹽及衍生物之組成物八週。
在本揭露之一些實施例中,可投予組成物至該個體一段足夠的期間,以預防或治療憂鬱症。該足夠的期間取決於該個體之種族、性別、體重或年齡、疾病之階段、症狀
或嚴重度、及投予的途徑、時機或頻率。在本揭露之一些實施例中,係每天投予該組成物超過至少一個月。例如,投予該組成物的期間可持續1、2、3、4或6個月、或1、2、3或4年,或甚至更長,只要在治療期間沒有副作用產生。在本揭露之例示性實施例中,該期間範圍係從4個星期至2年。在另一實施例中,該期間範圍可從2個月至12個月。在又一個實施例中,係每天投予苯甲酸或其鹽及衍生物12週。
本揭露之醫藥組成物可僅包含苯甲酸或其鹽及衍生物作為活性成分以預防或治療憂鬱症。易言之,苯甲酸或其鹽及衍生物作為該組成物中治療憂鬱症之唯一活性成分。在此實施例中,本揭露提供一種藉由單獨使用苯甲酸或其鹽及衍生物作為活性成分以預防或治療憂鬱症之安全且有效的療法。
或者,在另一實施例中,除非本揭露之療效受到抑制,否則該組成物可組合另一活性成分一起對個體投予。苯甲酸或其鹽及衍生物及其他的活性成分可由單一組成物或分開的組成物提供。所述組成物的例子包括苯甲酸鈉、苯甲酸阿格列汀(alogliptin benzoate)、苯甲酸倍他米松(betamethasone benzoate)、苯甲酸苄酯(benzyl benzoate)、鹽酸二甲雙胍(metformin hydrochloride)、鹽酸吡格列酮(pioglitazone hydrochloride)、苯甲酸利扎曲坦(rizatriptan benzoate)、苯乙酸鈉及其組合。
在一實施例中,本揭露的醫藥組成物以合適劑型製備,
其包含本揭露之有效量的醫藥組成物。
合適劑型的例子包括,但不限於口服給藥的錠劑、膠囊、著衣錠、顆粒、溶液和糖漿;經皮給藥的藥布、糊劑、乳膏和軟膏劑;直腸給藥的栓劑;和透過注射或噴霧途徑的無菌溶液。
合適劑型的另一例子包括,但不限於口服或注射途徑給藥的延釋劑或微脂粒基質。
劑型還可含有其他常規成分,例如防腐劑、安定劑、界面活性劑、緩衝劑、滲透壓調節鹽、乳化劑、甜味劑、著色劑、調味劑,但不以此為限。
在一實施例中,在本揭露所提供之方法中,苯甲酸或其鹽及衍生物之給藥可與任何合適的憂鬱症療法組合治療。
在本文中,使用數字或範圍列舉時,所屬技術領域中具有通常知識者應理解其意圖包含與本揭露相關的特定領域之適當合理範圍。
至少100mg至2500mg意味著該範圍內的所有整數單元量都是本揭露所具體揭示的一部分。因此,100、101、102、……250、251、252、……1000、1001、1002、……2497、2498、2499及2500單元量皆包含在本揭露的實施例中。
如本文中所使用,術語「治療」(treating)或「治療」(treatment)係指對有需要的個體投予有效量之苯甲酸或其鹽及衍生物,其目的係治癒、緩解、治療、改善、或預防該疾病、其症狀或罹患該疾病之傾向。該個體可由醫療
護理專業人員基於來自任何適當的診斷方法之結果而鑑定。
如本文中所使用,術語「有效量」係指為接受治療的個體賦予治療效果所需的活性成分的量。如所屬技術中具通常知識者所了解,該有效量會根據給藥途徑、賦形劑使用方式及其他治療方法共同使用的可能性而改變。
在本揭露的某些實施例中,該方法包括使用苯甲酸、苯甲酸鹽或其衍生物,其係選自由以下組成之群:苯甲酸鈉、苯甲酸鉀、苯甲酸鈣、苯甲酸鎂、2-胺基苯甲酸酯、3-胺基苯甲酸酯、4-胺基苯甲酸酯、4-羥基苯甲酸乙酯、4-羥基苯甲酸乙酯鈉、4-羥基苯甲酸丙酯、4-羥基苯甲酸丙酯鈉、4-羥基苯甲酸甲酯及4-羥基苯甲酸甲酯鈉,但不以此為限。
在本揭露的某些實施例中,苯甲酸或其鹽及衍生物係以口服劑型給藥。
已使用多個實例說明本揭露,以下的實例不應被視為限制本揭露所請之範圍。
本揭露檢驗苯甲酸鈉(一種DAAO抑制劑)治療重鬱症之功效及安全性。
在台灣進行了一項隨機雙盲安慰劑對照試驗。使用苯甲酸鈉或是安慰劑治療40位重鬱症病人八週,每個群組20位病人。在試驗前及第二、四、六及八週結束時,安排評估17題版漢式憂鬱量表(HAMD-17)(Hamilton 1960),
壓力知覺量表(perceived stress scale,PSS)及整體評估功能量表(global assessment of function,GAF)。
參與者
本研究為八週的先導性試驗,其目的為檢驗苯甲酸鈉對重鬱症的治療。經過徹底的醫學及神經診斷後,從事研究的精神科醫生對病患進行評估。診斷使用DSM-IV(精神疾病診斷與統計手冊-IV)之結構式診斷晤談量表(strucured clinical interview for DSM-IV,SCID)(美國精神醫學學會,1994),並招募以該DSM-IV(美國精神醫學學會,1994b)診斷出患有重鬱症的合格病患。所有的病患被隨機分成安慰劑或苯甲酸鈉(250至1500mg/天,例如250mg/天、500mg/天、750mg/天、1000mg/天、1250mg/天或1500mg/天)兩組。根據臨床的評估調整研究藥物之劑量。
評估
在第二、四、六和八週結束時,透過HAMD-17、PSS及GAF評估苯甲酸鈉對重鬱症的治療。
此外,透過兩週一次地(biweekly)常規身體和神經檢查及UKU(Udvalg for Kliniske Undersogelser)副作用量表(Lingjaerde,Ahlfors et al.1987)評估全面性副作用。在試驗開始前及第八週結束時檢查常規的實驗室試驗,其包括全血細胞計數(complete blood count,CBC)、生物化
學、尿液分析及心電圖(electrocardiogram,EKG)。
另外,在研究期間,每週透過面對面或電話訪談,進行安全性的臨床評估。如果研究的持續性被認為明顯更具風險而非有益的,由從事研究的精神科醫生或病患判斷而中途退出試驗。
數據分析
數據分析是基於治療意向分析法的原則。最後的觀察結果用來分析整個樣本中所有可用的數據(即,具有完整和不完整數據的案例)。所有顯著性差異的分析係使用0.05水準(雙側值)的第一型錯誤。兩個群組間的人口特徵、症狀基準值和試驗指標係藉由T檢定(或曼-惠特尼U檢定)比較連續變數及卡式檢定(或費雪精確檢定)而用於類別變數。
結果
如下表1所示,苯甲酸鈉組和安慰劑組的人口數據和教育水平是相似的(p大於0.05),且苯甲酸鈉試驗指標的平均劑量是775.0±213.1。
HAMD-17、GAF及PSS的評估結果如下表2所示。結果顯示,在第零週(baseline)時,兩群組病患的HAMD、GAF及PSS的平均±SD分數沒有顯著的差別。
然而,在HAMD-17分數上,發現了苯甲酸鈉組和安慰劑組(p=0.011)的基準值(baseline)和治療八週後的平均分數差異分別為7.5±4.9和2.8±6.1。可以看出苯甲酸鈉比起安慰劑療法在HAMD-17分數上提供了更佳的改善。
此外,在PSS分數上,發現了苯甲酸鈉組和安慰劑組(p=0.022)的基準值(baseline)和治療八週後的平均分數差異分別為6.4±9.9和0.4±4.6。可以看出苯甲酸鈉比起安
慰劑療法在PSS分數上提供了更佳的改善。
另外,在GAF分數上,發現了苯甲酸鈉組和安慰劑組(p=0.022)的基準值和治療八週後的平均分數差異分別為5.5±6.0和1.9±7.7。可以看出苯甲酸鈉比起安慰劑療法在GAF分數上提供了稍佳的改善。
縮寫:HAMD-17,17題版漢式憂鬱量表(17-item Hamilton Rating
Scale for Depression);GAF,整體評估功能量表(global assessment of function);PSS,壓力知覺量表(perceived stress scale)。
在上述使用苯甲酸鈉治療組的20位個體中,一名58歲男性在使用苯甲酸鈉八週後,他的HAMD-17分數從24減少至4,同時用來評估認知障礙的簡短智能測驗(mini-mental state examination,MMSE)分數從26改善至30。治療組中的另一個體,一名77歲老年男性的HAMD-17分數從31減少至15,共減少了16,同時MMSE分數從23改善到25。此外,一名80歲老年女性的HAMD-17分數從26減少到12,同時如同MMSE分數所示,改善了認知功能,從23增加到26。因此,苯甲酸鈉的治療不只改善了接受治療的個體的憂鬱症,還有他們的認知功能。
透過UKU副作用量表評估治療緊急的不良事件,而評估結果顯示,副作用輕微且不需醫療治療。它們被視為巧合。此外,在苯甲酸鈉的治療後,全血細胞計數(CBC)、生物化學、尿液分析及心電圖(EKG)測試的值皆在正常範圍內,沒有顯著的改變。沒有因為副作用而中途退出者。另外,一般抗憂鬱藥常見的副作用,像是噁心、焦慮、不安、心律不整、出汗及如便祕之消化道問題,都沒有在治療組的個體中發現。
上述詳盡的具體實施例僅闡釋以揭示本揭露之原理和作用,而不限制本揭露之範疇。所屬技術領域中具有通常知識者應了解,根據本揭露之揭示內容中之精神和原理的所有修飾和改變應落入所附加之申請專利範圍之範疇
內。說明書和實施例應認定為僅具例示性,而本揭露之實際範圍係由以下申請專利範圍所表示。
本案中所列之以下參考文獻係以個別併入之方式,各以引用方式併入本文。
American Psychiatric Association (1994) "Structured Clinical Interview for DSM-IV." American Psychiatric Press: Washington, DC.
Banerjee, S., J. Hellier, et al. (2011) "Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial." Lancet 378(9789): 403-411.
Bartlett, G. R. (1948) "The inhibition of d-amino acid oxidase by benzoic acid and various monosubstituted benzoic acid derivatives." J. Am. Chem. Soc. 70(3): 1010.
Beneyto, M. and J. H. Meador-Woodruff (2008) "Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder." Neuropsychopharmacology 33(9): 2175-2186.
Charney, D. S. (1998) "Monoamine dysfunction and the pathophysiology and treatment of depression." J. Clin. Psychiatry 59 Suppl. 14: 11-14.
Dagyte, G., J. A. Den Boer, et al. (2011) "The cholinergic system and depression." Behav. Brain Res.
221(2): 574-582.
Fukui, K. and Y. Miyake (1992) "Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase." J. Biol. Chem. 267(26): 18631-18638.
Guy, W. (1976) "ECDEU Assessment Manual for Psychopharmacology, revised." US Dept. Health, Education, and Welfare Publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health: 217-222.
Hamilton, M. (1960) "A rating scale for depression." J. Neurol Neurosurg Psychiatry 23: 56-62.
Harwood, D., K. Hawton, et al. (2001) "Psychiatric disorder and personality factors associated with suicide in older people: a descriptive and case-control study." Int. J. Geriatr. Psychiatry 16(2): 155-165.
IPCS (1993) "International Chemical Safety Card - Benzoic acid and sodium benzoate." Geneva, World Health Organization, International Programme on Chemical Safety (ICSC 0103).
Keller, M. B., P. W. Lavori, et al. (1992) "Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects." Arch. Gen. Psychiatry 49(10): 809-816.
Lingjaerde, O., U. G. Ahlfors, et al. (1987) "The UKU side effect rating scale. A new comprehensive rating scale
for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients." Acta Psychiatr. Scand. Suppl. 334: 1-100.
Mecocci, P., A. Cherubini, et al. (2004) "Depression in the elderly: new concepts and therapeutic approaches." Aging Clin. Exp. Res. 16(3): 176-189.
Miu, D. K. and C. K. Chan (2010) "Prognostic value of depressive symptoms on mortality, morbidity and nursing home admission in older people." Geriatr. Gerontol. Int. 11(2): 174-179.
Nowak, G., G. A. Ordway, et al. (1995) "Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims." Brain Res. 675(1-2): 157-164.
Ohayon, M. M. and A. F. Schatzberg (2003) "Using chronic pain to predict depressive morbidity in the general population." Arch. Gen. Psychiatry 60(1): 39-47.
Riihimaki, K. A., M. S. Vuorilehto, et al. (2014) "Five-year outcome of major depressive disorder in primary health care." Psychol. Med.: 1-11.
Saravay, S. M. and M. Lavin (1994) "Psychiatric comorbidity and length of stay in the general hospital. A critical review of outcome studies." Psychosomatics 35(3): 233-252.
Steffens, D. C., I. Skoog, et al. (2000) "Prevalence of depression and its treatment in an elderly population: the Cache County study." Arch. Gen. Psychiatry 57(6): 601-607.
Van den Berghe-Snorek, S. and M. T. Stankovich (1985) "Thermodynamic control of D-amino acid oxidase by benzoate binding." J. Biol. Chem. 260(6): 3373-3379.
Vanoni, M. A., A. Cosma, et al. (1997) "Limited proteolysis and X-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of D-amino acids catalyzed by mammalian D-amino acid oxidase." Biochemistry 36(I9): 5624-5632.
VanValkenburg, C., H. S. Akiskal, et al. (1984). "Anxious depressions. Clinical, family history, and naturalistic outcome - comparisons with panic and major depressive disorders." J. Affect. Disord. 6(1): 67-82.
Waern, M., B. S. Runeson, et al. (2002) "Mental disorder in elderly suicides: a case-control study." Am. J. Psychiatry 159(3): 450-455.
Claims (15)
- 一種用於預防或治療有需要的個體之憂鬱症之組成物,係包括有效量的苯甲酸或其鹽及衍生物和醫藥上可接受之賦形劑。
- 如申請專利範圍第1項所述之組成物,其中,該憂鬱症包括重度憂鬱症、老年憂鬱症、晚年憂鬱症及老年人憂鬱症。
- 如申請專利範圍第1項所述之組成物,其中,該治療改善個體的認知。
- 如申請專利範圍第1項所述之組成物,其中,該苯甲酸或其鹽及衍生物為苯甲酸鈉、苯甲酸鉀、苯甲酸鈣、苯甲酸鎂、2-胺基苯甲酸酯、3-胺基苯甲酸酯、4-胺基苯甲酸酯、4-羥基苯甲酸乙酯、4-羥基苯甲酸乙酯鈉、4-羥基苯甲酸丙酯、4-羥基苯甲酸丙酯鈉、4-羥基苯甲酸甲酯或4-羥基苯甲酸甲酯鈉。
- 如申請專利範圍第1項所述之組成物,其中,該苯甲酸鹽為苯甲酸鈉。
- 如申請專利範圍第1項所述之組成物,其中,投予至該個體之苯甲酸或其鹽及衍生物的量為100毫克/天至2500毫克/天。
- 如申請專利範圍第6項所述之組成物,其中,投予至該個體之苯甲酸或其鹽及衍生物的量為250毫克/天至1500毫克/天。
- 如申請專利範圍第7項所述之組成物,其中,投予至 該個體之苯甲酸或其鹽及衍生物的量為500毫克/天至1000毫克/天。
- 如申請專利範圍第1項所述之組成物,其中,該醫藥上可接受之賦形劑係選自由填料、黏合劑、防腐劑、崩散劑、潤滑劑、懸浮劑、潤濕劑、溶劑、界面活性劑、酸、調味劑、聚乙二醇、烷二醇、癸二酸、二甲基亞碸、醇及其任一組合所組成之群組中之一者。
- 如申請專利範圍第1項所述之組成物,其中,該苯甲酸或其鹽及衍生物作為該組成物中預防或治療該憂鬱症之唯一活性成分。
- 如申請專利範圍第1項所述之組成物,其中,該苯甲酸或其鹽及衍生物係與治療或預防該憂鬱症之其他活性成分併用。
- 如申請專利範圍第11項所述之組成物,其中,該其他活性成分係選自由度洛西汀(duloxetine)、左旋米那普侖(levomilnacipran)、文拉法辛(venlafaxine)、琥珀酸去甲文拉法辛(desvenlafaxine)、西酞普蘭(citalopram)、艾司西酞普蘭(escitalopram)、氟西汀(fluoxetine)、氟伏沙明(fluvoxamine)、帕羅西汀(paroxetine)、舍曲林(sertraline)、阿米替林(amitriptyline)、安莫散平(amoxapine)、氯米帕明(clomipramine)、地昔帕明(desipramine)、多慮平(doxepin)、伊米帕明(imipramine)、去甲替林(nortriptyline)、普羅替林(protriptyline)、曲米帕 明(trimipramine)、馬普替林(maprotiline)、安非他酮(bupropion)、維拉佐酮(vilazodone)、奈法唑酮(nefazodone)、曲唑酮(trazodone)、沃替西汀(vortioxetine)、異卡波肼(isocarboxazid)、苯乙肼(phenelzine)、司來吉蘭(selegiline)、反苯環丙胺(tranylcypromine)、米氮平(mirtazapine)、奧氮平(olanzapine)、喹硫平(quetiapine)、阿立哌唑(aripiprazole)、舒必利(sulpiride)、氟哌噻噸(flupentixol)、美利曲辛(melitracen)、阿戈美拉汀(agomelatine)、嗎氯貝胺(moclobemide)、貫葉連翹(St.John's wort)、S-腺苷甲硫氨酸(S-adenosyl-L-methionine)及其任一組合所組成之群組中之一者。
- 如申請專利範圍第1項所述之組成物,其中,該苯甲酸或其鹽及衍生物的投予與該憂鬱症之其他療程結合。
- 如申請專利範圍第13項所述之組成物,其中,該其他療程係選自由心理治療、電痙攣療法、腦刺激療法、光照治療及其任一組合所組成之群組中之一者。
- 如申請專利範圍第14項所述之組成物,其中,該腦刺激療法係腦深層刺激、侵入性迷走神經刺激、透顱磁刺激、透顱直流電刺激、透顱交流電刺激、電痙攣療法、磁振癲癇發作治療、經顱微電流刺激療法或非侵入性迷走神經刺激。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762589933P | 2017-11-22 | 2017-11-22 | |
US62/589,933 | 2017-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202206061A true TW202206061A (zh) | 2022-02-16 |
Family
ID=66631699
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107141674A TWI752282B (zh) | 2017-11-22 | 2018-11-22 | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 |
TW110139097A TW202206061A (zh) | 2017-11-22 | 2018-11-22 | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107141674A TWI752282B (zh) | 2017-11-22 | 2018-11-22 | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11826326B2 (zh) |
EP (1) | EP3713556A4 (zh) |
JP (2) | JP7034314B2 (zh) |
KR (2) | KR20200088861A (zh) |
CN (1) | CN111491627A (zh) |
AU (1) | AU2018371628B2 (zh) |
CA (1) | CA3076180C (zh) |
MY (1) | MY197404A (zh) |
TW (2) | TWI752282B (zh) |
WO (1) | WO2019103597A1 (zh) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3037010A1 (en) * | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
US8974365B2 (en) * | 2012-11-25 | 2015-03-10 | Steven Richard Devore Best | Treatment of thalamocortical dysrhythmia |
EP2808023A1 (en) * | 2013-05-30 | 2014-12-03 | Université Pierre et Marie Curie (Paris 6) | New drug for the treatment and/or prevention of depressive disorders |
PT3094616T (pt) | 2014-01-17 | 2021-03-03 | Univ Rush Medical Center | O uso de uma composição que contém tribenzoato de glicerilo em distúrbios neurodegenerativos |
WO2015147742A1 (en) | 2014-03-24 | 2015-10-01 | Kaohsiung Chang Gung Memorial Hospital | Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment |
JP6958922B2 (ja) | 2016-06-13 | 2021-11-02 | シニュークス インターナショナル(タイワン)コーポレイション | 安息香酸ナトリウムの共結晶及びその使用 |
US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
CN108553456B (zh) | 2016-12-29 | 2020-09-15 | 天津中医药大学 | 苯甲酸及其衍生物的用途 |
JP6550426B2 (ja) * | 2017-07-26 | 2019-07-24 | カオシュン・チャン・グン・メモリアル・ホスピタル | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 |
-
2018
- 2018-11-22 KR KR1020207017290A patent/KR20200088861A/ko active Application Filing
- 2018-11-22 TW TW107141674A patent/TWI752282B/zh active
- 2018-11-22 WO PCT/MY2018/000035 patent/WO2019103597A1/en unknown
- 2018-11-22 CA CA3076180A patent/CA3076180C/en active Active
- 2018-11-22 KR KR1020237010646A patent/KR20230047509A/ko not_active Application Discontinuation
- 2018-11-22 EP EP18881272.1A patent/EP3713556A4/en active Pending
- 2018-11-22 TW TW110139097A patent/TW202206061A/zh unknown
- 2018-11-22 JP JP2020546266A patent/JP7034314B2/ja active Active
- 2018-11-22 AU AU2018371628A patent/AU2018371628B2/en active Active
- 2018-11-22 US US16/766,314 patent/US11826326B2/en active Active
- 2018-11-22 MY MYPI2020001418A patent/MY197404A/en unknown
- 2018-11-22 CN CN201880072395.2A patent/CN111491627A/zh active Pending
-
2022
- 2022-03-01 JP JP2022031267A patent/JP7312286B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
TW201924667A (zh) | 2019-07-01 |
KR20200088861A (ko) | 2020-07-23 |
JP2022071083A (ja) | 2022-05-13 |
EP3713556A4 (en) | 2021-10-20 |
KR20230047509A (ko) | 2023-04-07 |
WO2019103597A8 (en) | 2019-11-21 |
US11826326B2 (en) | 2023-11-28 |
WO2019103597A1 (en) | 2019-05-31 |
US20200360321A1 (en) | 2020-11-19 |
JP7034314B2 (ja) | 2022-03-11 |
AU2018371628B2 (en) | 2021-08-12 |
CA3076180A1 (en) | 2019-05-31 |
AU2018371628A1 (en) | 2020-04-09 |
EP3713556A1 (en) | 2020-09-30 |
MY197404A (en) | 2023-06-16 |
JP2021504471A (ja) | 2021-02-15 |
TWI752282B (zh) | 2022-01-11 |
JP7312286B2 (ja) | 2023-07-20 |
CA3076180C (en) | 2022-05-17 |
CN111491627A (zh) | 2020-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Feighner et al. | Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression | |
Mann et al. | L-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression | |
Bellino et al. | Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study | |
Reimherr et al. | A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients | |
MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
JP2009500421A (ja) | エスゾピクロン及び抗うつ薬の組み合わせ | |
JP2007513169A (ja) | 自殺傾向を予防しまたは減少させるための、および自殺傾向に関連する大うつ病を治療するためのメマンチン | |
CA3075719A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
CN113710319A (zh) | 用于治疗焦虑相关病症的组合物和方法 | |
CN107949379A (zh) | L‑4‑氯代犬尿氨酸的治疗用途 | |
JPH0227327B2 (zh) | ||
Abad et al. | Pharmacological treatment of sleep disorders and its relationship with neuroplasticity | |
WO2012056246A1 (en) | Combination treatment of major depressive disorder | |
TWI752282B (zh) | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 | |
EP3096790B1 (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
US20230149392A1 (en) | Treatment of major depressive disorder | |
JP2009539941A (ja) | Slv308およびl−dopaを含んでなる組み合わせ製剤 | |
WO2023215338A1 (en) | Compositions and methods for treating cluster headache | |
WO2023215344A2 (en) | Compositions and methods for treating cluster-tic syndrome | |
JP2017088584A (ja) | 医薬組成物 | |
WO2023215342A1 (en) | Compositions and methods for treating trigeminal neuralgia | |
Kuśnierz et al. | Depression and its treatment with trazodone | |
KR20240093852A (ko) | 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료 | |
CN118401239A (zh) | 用于治疗抑郁症,包括难治性抑郁症的2-氟脱氯氯胺酮 |